We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Astrazeneca Plc | LSE:AZN | London | Ordinary Share | GB0009895292 | ORD SHS $0.25 |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -6.00 | -0.05% | 12,166.00 | 12,132.00 | 12,136.00 | 12,198.00 | 12,076.00 | 12,180.00 | 1,644,408 | 16:35:22 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 45.81B | 5.96B | 3.8415 | 31.59 | 188.1B |
From May 2021 to May 2024
AstraZeneca PLC's coronavirus vaccine contributed $0.01 to earnings per share in the third quarter, though the company lost $0.03 per share from its development since the start of the year. "AstraZeneca Swung to 3Q Loss Despite Higher Revenue; Continues to Lose Money From Covid-19 Vaccine," at 0741 GMT, incorrectly said that development of the vaccine shaved $0.01 off earnings in the third quarter.
(END) Dow Jones Newswires
November 12, 2021 04:52 ET (09:52 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Astrazeneca Chart |
1 Month Astrazeneca Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
